BioCentury

7:00 AM GMT, Jul 30, 2007
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulation

GPC chronicles

GPC chronicles

GPC (FSE:GPC; GPCB), which was founded in 1997, originally was a genomics- and proteomics-based drug discovery company focused on oncology, infectious diseases and immunology. Since it in-licensed Orplatna satraplatin in 2002, its focus has turned to oncology drug discovery and development. At March 31, GPC had E111.3 million ($148.8 million) in cash. The weekly stock price for GPC is tracked below against selected events since the company's IPO on the Neuer Markt of the Frankfurt Stock Exchange in

Read the full 792 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.